GPR-C5D-CARTY: A Next-Line Therapy for Low-Level Disease

In this episode, we discuss the latest updates on CAR T-cell therapy in multiple myeloma, including the studies presented at ASCO and EHA 2023. Here are the show notes:

1. For a primer on CAR T-cell therapy, listen to our episode aired on July 22nd 2022 with Dr. Surbhi Sidana: https://share.transistor.fm/s/efc4acf9

2. RCTs of BCMA CAR T-cell Therapy in Early Relapsed Multiple Myeloma:

a) KarMMa-3 (ide-cel): https://pubmed.ncbi.nlm.nih.gov/36762851/

b) CARTITUDE-4 (cilta-cel): https://pubmed.ncbi.nlm.nih.gov/37272512/

3. Clinical trials of GPRC5D CAR T-cell therapy in multiple myeloma:

a) MCARH109 (MSKCC Trial): https://pubmed.ncbi.nlm.nih.gov/36170501/

b) POLARIS Trial: https://pubmed.ncbi.nlm.nih.gov/36725117/

3. Phase 1 UNIVERSAL trial of ALLO-715 in Multiple Myeloma:
https://pubmed.ncbi.nlm.nih.gov/36690811/

4. Anti BCMA/CD19 CAR T-cells with IMiD maintenance therapy in myeloma:
https://pubmed.ncbi.nlm.nih.gov/36413381/